期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 216, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.113307
关键词
Human prostate cancer; PROTAC; Androgen receptor; E3 ligand; VHL ligand
资金
- National Science Foundation of China [22071087, 21772084]
- Fundamental Research Funds for the Central Universities [lzujbky-2017-k06]
- Thousand Young Talents Programand Longyuan Talent Program
A031 is a highly effective androgen receptor degrader that induces the degradation of AR protein in VCaP cell lines in a time-dependent manner with an IC50 value of less than 0.25 mM. It is 5 times less toxic than EZLA and shows significant inhibitory effects on tumor growth in zebrafish transplanted with human prostate cancer (VCaP), providing a promising candidate for developing novel drugs for prostate cancer.
Androgen receptor (AR) is an effective therapeutic target for the treatment of prostate cancer. We report herein the design, synthesis, and biological evaluation of highly effective proteolysis targeting chimeras (PROTAC) androgen receptor (AR) degraders, such as compound A031. It could induce the degradation of AR protein in VCaP cell lines in a time-dependent manner, achieving the IC 50 value of less than 0.25 mM. The A031 is 5 times less toxic than EZLA and works with an appropriate half-life (t 1/2) or clearance rate (Cl). Also, it has a significant inhibitory effect on tumor growth in zebrafish transplanted with human prostate cancer (VCaP). Therefore, A031 provides a further idea of developing novel drugs for prostate cancer. (C) 2021 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据